Matching slides 303,780
Current window 203,161-203,190
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

203,161-203,190 of 303,780

filter-aware
06
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
07
The slide uses a hierarchical diagram to map the clinical manifestations of the disease.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
08
The diagram illustrates the metabolic pathway and the specific block at the Cystathionine beta-synthase step.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
09
The table contrasts clinical outcomes (Hcy levels, lens dislocation, IQ, thrombosis, mortality) between two patient cohorts.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
10
Includes a citation of the specific clinical guidelines paper.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
11
Includes historical context of diagnostic methods (pre-NBS era).Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
12
The slide uses a table to show symptom overlap (+) and absence (-) between two conditions, accompanied by a visual comparison of patients.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
13
The slide highlights the clinical consequences of missing HCU in newborn screening (NBS).Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
14
The slide displays various medical nutrition products used for HCU management.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
15
Includes a clinical photograph of two patients, likely illustrating physical manifestations or growth issues associated with the condition.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
16
Case study format used to illustrate the consequences of poor disease management.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
17
The slide uses a list-based approach to describe the disease burden, paired with a visual column of key clinical manifestations.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
18
The slide uses a simple problem-solution structure, identifying the clinical gap and the resulting need.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
19
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
20
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
21
The slide uses a pie chart to show patient segmentation by B6 responsiveness and a timeline/number-line to show age of diagnosis, followed by key metrics on complication rates.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
22
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
23
The slide uses a process flow diagram to show the metabolic block (CBS deficiency) and the therapeutic intervention point.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
24
The slide uses a biological process diagram to contrast normal intracellular metabolism with the therapeutic effect of the drug in the plasma.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
25
The slide uses a process flow diagram to represent clinical trial cohorts and study design.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
26
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
27
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
01
Slide 1
Albireo Pharma | Results Presentation Deck | 18 slidesAlbireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations 1 hit
02
Albireo Pharma | Results Presentation Deck | 18 slidesAlbireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations 1 hit
03
Albireo Pharma | Results Presentation Deck | 18 slidesAlbireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations 1 hit
06
Includes a photo of a child with medical equipment to humanize the disease impact.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · Problem1 hit
07
The slide outlines a standard randomized controlled trial (RCT) design for a pharmaceutical study.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · Agitate1 hit
08
The slide includes a footer note regarding patient completion rates.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · Agitate1 hit
09
Clinical trial data showing efficacy of Odevixibat (Bylvay) vs Placebo.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
10
The chart displays LS Mean (95% CI) with p-value significance markers.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit